Fig. 1 · Structure

Documents & Downloads

STAT3-IN-1

Cat. No. A12232 CAS 2059952-75-7

STAT3 inhibitor

STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis.

In Stock

Publications for STAT3-IN-1

2 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Rongshou Wu, .et al. , Sci Rep, 2023, 13: 16998 PMID: 37813900

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Stat-3 1.82 μM (IC50, in HT29 cells)
Stat-3 2.14 μM (IC50, in MDA-MB 231 cells)

STAT3-IN-1 Research Summary

This section summarizes 2 in vitro studies of STAT3-IN-1 from 1 published reference. In vitro models include mouse gastric dysplastic Meta4 organoids derived from Mist1-Kras mice.

STAT3-IN-1 In Vitro Studies

In mouse gastric dysplastic Meta4 organoids, STAT3-IN-1 (1 μM, 3 days) arrested growth without inducing cell death. A separate comparison using STAT3-IN-1 (500 nM) with trametinib (1 μM) for 3 days produced cell death. These findings distinguish single-agent growth suppression from the combination response in this model. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Single-agent response in mouse gastric dysplastic organoids

Cell-based study · Mouse gastric dysplastic Meta4 organoids derived from Mist1-Kras mice [1]

STAT3-IN-1 arrested organoid growth without inducing cell death in the reported three-day comparison. DMSO, pyrvinium, Stattic and cryptotanshinone were parallel controls/comparators.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Organoid diameter and morphology before and after treatmentQualitative growth and survival response Growth arrest without cell death[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
3 days
Method
Organoid exposure followed by imaging and diameter assessment
Vehicle
DMSO vehicle control
Reported limits
Final DMSO fraction and organoid-level sample count are not specified in the read Figure 3F–G caption. The caption states n = 3 biological replicates; shared methods state experiments were repeated three times.
Methods and source locations

Compound reported in the paper: STAT3-IN-1; Compound label in the paper: STAT3-IN-1

Results apply to the reported supplier-named reagent in these organoids; chemical purity, stereochemical composition and equivalence to an Adooq lot were not established.

Figure 3F–G; associated Results; Methods: Organoid culture and Quantification and Statistical Analysis

Organoid diameter and morphology before and after treatment: Phase-contrast images and ImageJ diameter measurements; Figure 3F–G. No exact diameters inferred from violin plots. — Figure 3F–G and associated Results paragraph beginning “We additionally treated the Meta3 and Meta4 organoids”

STAT3-IN-1 plus trametinib in mouse gastric dysplastic organoids

Cell-based study · Mouse gastric dysplastic Meta4 organoids derived from Mist1-Kras mice [1]

Combined STAT3-IN-1 and trametinib produced cell death and reduced organoid size in the reported comparison with DMSO and individual treatments. This is a combination result.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Organoid diameter and morphology before and after single or combined treatmentQualitative combination response Co-treatment induced cell death; the authors described an effect comparable to pyrvinium[1]

Literature-Reported Treatment Conditions

Treatment concentration
STAT3-IN-1: 500 nM; trametinib: 1 μM
Exposure duration
3 days
Method
Organoid exposure to individual agents or their combination
Vehicle
DMSO vehicle control
Co-treatment
Trametinib (Tra), 1 μM, co-treatment
Reported limits
Final DMSO fraction and organoid-level sample count are not specified in the read Figure 3H–I caption. The caption states n = 3 biological replicates; shared methods state experiments were repeated three times.
Methods and source locations

Compound reported in the paper: STAT3-IN-1; Compound label in the paper: STAT3-IN-1; Tra + STAT3-IN-1

Results apply to the reported supplier-named reagent in these organoids; chemical purity, stereochemical composition and equivalence to an Adooq lot were not established.

Figure 3H–I; associated Results; Methods: Organoid culture and Quantification and Statistical Analysis

Organoid diameter and morphology before and after single or combined treatment: Phase-contrast imaging and ImageJ diameter assessment in Figure 3H–I; no numerical effect size or synergy score inferred. — Figure 3H–I and associated Results paragraph contrasting single inhibitors with co-treatment

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 2059952-75-7
Applications STAT3 inhibitor
Formula C28H29NO6
Molecular Weight 475.53
SMILES
COC1=CC(OC)=CC(/C=C/C2=CC=C(NC(/C=C/C3=CC(OC)=C(OC)C(OC)=C3)=O)C=C2)=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 81 mg/mL (170.33 mM)
Water Insoluble
Ethanol 4 mg/mL (8.41 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

STAT3-IN-1 Research References

  1. [1] Hyesung Kim, Bogun Jang, Changqing Zhang, et al. Targeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis Gastroenterology (2024). PMID: 37802423 DOI: 10.1053/j.gastro.2023.09.040 Source material

Publications

2 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Rongshou Wu, .et al. , Sci Rep, 2023, 13: 16998 PMID: 37813900

Added to your cart

View Cart Checkout
Loading...